{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:43:25Z","timestamp":1778867005077,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"NEI","doi-asserted-by":"publisher","award":["\/ NEI P30 EY002162"],"award-info":[{"award-number":["\/ NEI P30 EY002162"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"NEI","doi-asserted-by":"publisher","award":["K12EY031372"],"award-info":[{"award-number":["K12EY031372"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008069","name":"University of California, San Francisco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaapos.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of American Association for Pediatric Ophthalmology and Strabismus"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jaapos.2022.08.524","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T13:48:29Z","timestamp":1666014509000},"page":"305.e1-305.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity"],"prefix":"10.1016","volume":"26","author":[{"given":"Charis","family":"Hoppe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derick G.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin F.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumeer","family":"Thinda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sriranjani P.","family":"Padmanabhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3945-2077","authenticated-orcid":false,"given":"Julius T.","family":"Oatts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.jaapos.2022.08.524_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/pr.2013.204","article-title":"Preterm birth-associated neurodevelopmental impairment estimates at regional and global levels for 2010","volume":"74","author":"Blencowe","year":"2013","journal-title":"Pediatr Res"},{"key":"10.1016\/j.jaapos.2022.08.524_bib2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF02482615","article-title":"Results of U.S. randomized clinical trial of cryotherapy for ROP (CRYO-ROP)","volume":"74","author":"Palmer","year":"1990","journal-title":"Doc Ophthalmol Adv Ophthalmol"},{"key":"10.1016\/j.jaapos.2022.08.524_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ajo.2021.07.016","article-title":"Retinopathy of prematurity: advances in the screening and treatment of retinopathy of prematurity using a single center approach","volume":"233","author":"Berrocal","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jaapos.2022.08.524_bib4","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1001\/archopht.1990.01070120056029","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome\u2014structure and function. Cryotherapy for Retinopathy of Prematurity Cooperative Group","volume":"108","year":"1990","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jaapos.2022.08.524_bib5","first-page":"233","article-title":"Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.jaapos.2022.08.524_bib6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaapos.2022.08.524_bib7","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00417-010-1430-x","article-title":"Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage","volume":"248","author":"Nazari","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"issue":"9","key":"10.1016\/j.jaapos.2022.08.524_bib8","first-page":"1080","article-title":"Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes","volume":"28","author":"Chen","year":"2014","journal-title":"Eye Lond Engl"},{"key":"10.1016\/j.jaapos.2022.08.524_bib9","first-page":"124","article-title":"Early Treatment for Retinopathy of Prematurity Cooperative Group. Progression of myopia and high myopia in the Early Treatment for Retinopathy of Prematurity study: findings at 4 to 6 years of age","volume":"17","author":"Quinn","year":"2013","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.jaapos.2022.08.524_bib10","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jaapos.2022.08.524_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/EB.S189684","article-title":"Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity","volume":"11","author":"Patel","year":"2019","journal-title":"Eye Brain"},{"key":"10.1016\/j.jaapos.2022.08.524_bib12","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","article-title":"Pediatric Eye Disease Investigator Group. A dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments","volume":"125","author":"Wallace","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2022.08.524_bib13","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3928\/23258160-20160229-12","article-title":"Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab","volume":"47","author":"Snyder","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jaapos.2022.08.524_bib14","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical management of recurrent retinopathy of prematurity following intravitreal bevacizumab monotherapy","volume":"123","author":"Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2022.08.524_bib15","first-page":"88.e1","article-title":"Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP","volume":"23","author":"Anand","year":"2019","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.jaapos.2022.08.524_bib16","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaapos.2022.08.524_bib17","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","article-title":"Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial","volume":"172","author":"Stahl","year":"2018","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jaapos.2022.08.524_bib18","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jaapos.2022.08.524_bib19","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.4103\/ijo.IJO_3016_20","article-title":"Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity","volume":"69","author":"Gangwe","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jaapos.2022.08.524_bib20","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3928\/01913913-20190501-01","article-title":"Persistent avascular retina in infants with a history of type 2 retinopathy of prematurity: to treat or not to treat?","volume":"56","author":"Al-Taie","year":"2019","journal-title":"J\u00a0Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.jaapos.2022.08.524_bib21","first-page":"1","article-title":"Various versatile variances: an object-oriented implementation of clustered covariances in R","volume":"95","author":"Zeileis","year":"2020","journal-title":"J\u00a0Stat Softw"},{"key":"10.1016\/j.jaapos.2022.08.524_bib22","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","article-title":"Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy","volume":"40","author":"Ling","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.jaapos.2022.08.524_bib23","unstructured":"Chiang MF, Quinn GE, Fielder AR, et\u00a0al. International Classification of Retinopathy of Prematurity, Third Edition. Ophthalmology 2021;128:e51-68."},{"key":"10.1016\/j.jaapos.2022.08.524_bib24","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.ophtha.2005.03.025","article-title":"Prevalence of myopia at 9 months in infants with high-risk prethreshold retinopathy of prematurity","volume":"112","author":"Davitt","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2022.08.524_bib25","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archopht.124.6.766","article-title":"Prevalence and course of strabismus in the first year of life for infants with prethreshold retinopathy of prematurity: findings from the Early Treatment for Retinopathy of Prematurity study","volume":"124","author":"VanderVeen","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jaapos.2022.08.524_bib26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/09273972.2019.1604773","article-title":"Global and regional prevalence of strabismus: a comprehensive systematic review and meta-analysis","volume":"27","author":"Hashemi","year":"2019","journal-title":"Strabismus"},{"key":"10.1016\/j.jaapos.2022.08.524_bib27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ajo.2021.11.015","article-title":"Real-world visual outcomes of laser and anti-VEGF treatments for retinopathy of prematurity","volume":"238","author":"Gundlach","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jaapos.2022.08.524_bib28","first-page":"536","article-title":"Prevalence and course of strabismus through age 6 years in participants of the Early Treatment for Retinopathy of Prematurity randomized trial","volume":"15","author":"VanderVeen","year":"2011","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.jaapos.2022.08.524_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/archopht.116.3.329","article-title":"Strabismus in premature infants in the first year of life. Cryotherapy for Retinopathy of Prematurity Cooperative Group","volume":"116","author":"Bremer","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jaapos.2022.08.524_bib30","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3341\/kjo.2018.0011","article-title":"Anti-vascular endothelial growth factor treatment of retinopathy of prematurity: efficacy, safety, and anatomical outcomes","volume":"32","author":"Kang","year":"2018","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.jaapos.2022.08.524_bib31","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00006982-200406000-00006","article-title":"Retinal detachment of regressed retinopathy of prematurity in children aged 2 to 15 years","volume":"24","author":"Park","year":"2004","journal-title":"Retina"},{"key":"10.1016\/j.jaapos.2022.08.524_bib32","first-page":"96","article-title":"Late retinal complications in former preterm infants with regressed ROP [in German]","volume":"221","author":"Jandeck","year":"2004","journal-title":"Klin Monatsbl Augenheilkd"}],"container-title":["Journal of American Association for Pediatric Ophthalmology and Strabismus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109185312200711X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109185312200711X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:37:16Z","timestamp":1778798236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109185312200711X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S109185312200711X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaapos.2022.08.524","relation":{},"ISSN":["1091-8531"],"issn-type":[{"value":"1091-8531","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity","name":"articletitle","label":"Article Title"},{"value":"Journal of American Association for Pediatric Ophthalmology and Strabismus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaapos.2022.08.524","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}